Orthofix Medical Inc. filed an 8-K with the U.S. Securities and Exchange Commission on November 9, 2026, disclosing its financial results for the third quarter ended September 30, 2026, through a press release furnished as Exhibit 99.1.

Key Highlights

  • Filing date: November 9, 2026, covering results for the quarter ended September 30, 2026.
  • Exchange listing: Orthofix Medical common stock, $0.10 par value per share, trades on the Nasdaq Global Select Market under the symbol OFIX (NASDAQ:OFIX).
  • Non-GAAP framework: The company disclosed seven distinct non-GAAP measures it uses alongside GAAP results, including Constant Currency, Free Cash Flow, Adjusted EBITDA, and Adjusted Gross Margin.
  • SeaSpine merger context: The company identified costs related to its merger with SeaSpine Holdings Corporation, consummated in January 2023, as an ongoing non-GAAP adjustment category.
  • M6 product line exit: Operating losses, impairments, and restructuring charges tied to the discontinued M6 artificial disc product lines are excluded from non-GAAP operating results.
  • Adjusted EBITDA designation: The filing states that Adjusted EBITDA "is the primary metric used by the Company's chief operating decision maker in managing the business."
  • Exhibit status: The press release and Item 2.02 disclosure are furnished, not filed, and are not subject to Section 18 liabilities of the Exchange Act.

Orthofix Discloses Q3 2026 Results and Non-GAAP Measurement Framework

Orthofix Medical Inc., a Lewisville, Texas-based medical device company incorporated in Delaware, issued a current report on November 9, 2026, attaching a press release that announced financial results for the three months ended September 30, 2026. The company operates across spinal and orthopedic product lines and completed its combination with SeaSpine Holdings Corporation in January 2023, an event whose integration costs continue to appear as a named adjustment in the company's non-GAAP reconciliations.

The 8-K's principal substantive content is a detailed explanation of the non-GAAP financial measures the company uses to evaluate performance. Free Cash Flow is defined in the filing as cash flow from operating activities minus capital expenditures, and management uses it, the filing states, "to measure progress on its capital efficiency and cash flow initiatives." Constant Currency is calculated by applying foreign currency rates from the comparable prior-year period to current net sales, allowing management to analyze revenue without the influence of exchange-rate movements. Adjusted Gross Margin represents adjusted gross profit expressed as a percentage of GAAP net sales.

The filing also details categories of items excluded from non-GAAP figures. These include share-based compensation, described as "primarily a non-cash expense"; foreign exchange gains and losses recorded in other income (expense), net; SeaSpine merger-related costs such as integration, severance, retention, and professional fees; and operating results tied to the discontinued M6 artificial disc product lines. Additional exclusions cover strategic investment costs unrelated to the SeaSpine merger, acquisition-related fair value adjustments on contingent consideration, and amortization or depreciation of long-lived assets acquired in business combinations. The filing notes that the actual financial figures from the press release are contained in Exhibit 99.1, which is furnished but not filed for purposes of Exchange Act liability.

What Was Disclosed

Orthofix Medical filed an 8-K on November 9, 2026, furnishing a press release with third-quarter 2026 results as Exhibit 99.1. The filing's body provided an extensive glossary of seven non-GAAP financial measures and the specific adjustment categories applied to each, referencing the January 2023 SeaSpine merger and the exited M6 artificial disc product lines as sources of recurring non-GAAP exclusions.